Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan

被引:20
作者
Ajiki, W
Tsukuma, H
Oshima, A
Kawa, K
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Canc Control & Stat, Osaka Canc Registry, Higashinari Ku, Osaka 5378511, Japan
[2] Osaka Med Ctr Maternal & Childhood Hlth, Osaka, Japan
关键词
incidence; mortality; neuroblastoma; screening;
D O I
10.1023/A:1008897123707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To evaluate the effects of mass screening for neuroblastoma, time trends of incidence, mortality, and survival of neuroblastoma in Osaka Prefecture were analyzed. Methods: Data for this analysis was obtained from the population-based Osaka Cancer Registry. Time trends of incidence and mortality rates were analyzed by calendar year and by birth cohort. Survival was compared between before and after the introduction off systematic screening. Results: From 1970-94, 457 cases of neuroblastoma and 182 deaths from neuroblastoma were observed in Osaka. The annual age-standardized incidence rate per million children increased from 7.5 in 1970-84 to 20.5 in 1985-94, while the mortality rates did not differ between these two periods. Analysis by birth cohort showed that the incidence rate at 0 year of age per 100,000 live births increased from 2.30 in 1970-79 (unscreened) to 19.80 in 1988-89 (screening by high-performance liquid chromatography, HPLC). The incidence rate in children 1 and 2-4 years of age also increased according to the introduction of HPLC. The mortality rate in children 1-4 years of age per 100,000 live births slightly decreased from 3.87 in 1970-79 to 3.30 in 1988-89, which was presumed to be derived from the improvement in survival due to the progress in treatment. Conclusions: It is strongly suggested that mass screening for neuroblastoma causes harm because of overdiagnosis, and it has little effect on decreasing the incidence and the mortality of neuroblastoma at 1-4 years of age.
引用
收藏
页码:631 / 636
页数:6
相关论文
共 17 条
[1]  
[Anonymous], [No title captured]
[2]   A POPULATION-BASED STUDY OF NEUROBLASTOMA INCIDENCE, SURVIVAL, AND MORTALITY IN NORTH-AMERICA [J].
BERNSTEIN, ML ;
LECLERC, JM ;
BUNIN, G ;
BRISSON, L ;
ROBISON, L ;
SHUSTER, J ;
BYRNE, T ;
GREGORY, D ;
HILL, G ;
DOUGHERTY, G ;
SCRIVER, C ;
LEMIEUX, B ;
TUCHMAN, M ;
WOODS, WG .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :323-329
[3]  
Bessho F, 1996, INT J CANCER, V67, P520, DOI 10.1002/(SICI)1097-0215(19960807)67:4<520::AID-IJC10>3.0.CO
[4]  
2-B
[5]  
Gurney JG, 1996, CANCER, V78, P532
[6]  
*HLTH WELF STAT AS, 1997, KOK EIS NO DOK
[7]  
[Jensen OM. IARC publication IARC publication], 1991, CANC REGISTRATION PR
[9]  
Nishi M, 1997, INT J CANCER, V71, P552, DOI 10.1002/(SICI)1097-0215(19970516)71:4<552::AID-IJC8>3.0.CO
[10]  
2-T